Regkirona COVID-19 Drug Claimed to be Effective in Preventing COVID-19 Severity and Death

Liputan6.com, Jakarta To stop the spread of the Corona virus COVID-19 in the body, needed COVID-19 medicine which can prevent the severity after infection COVID-19. One way to prevent patients from being hospitalized to reduce the risk of death is Regkirona monoclonal antibody therapy.

What is Regkirona monoclonal antibody treatment? According to the Executive Director of Dexa Laboratories of Biomolecular Sciences, Dr. Raymond Tjandrawinata, this drug is made from convalescent plasma collected from COVID-19 survivors from South Korea. “The patient’s blood is then filtered, using special technology to produce the Regkirona monoclonal antibody.”

The difference with other drugs used for COVID-19, said Raymond, is that there is no specific research on the COVID-19 virus. While the Regkirona drug is more focused on the Sars-Cov-2 virus, its development also involves experiments on other COVID-19 variants such as Alpha, Beta, Gamma, and Delta.

“This monoclonal Regkirona has the ability to prevent the binding of ACE2 to the receptor. As is known, when ACE2 meets the receptor, the virus that enters can enter the lungs,” he said.

“So this drug works by blocking, the virus must not bind to the receptor. For this reason, patients at high risk of being infected with COVID-19 such as people with hypertension, diabetes, obesity, asthma, kidney disorders and so on can use this treatment,” he said.

This new drug developed in Korea, continued Raymond, can reduce the death rate by up to 2 times. “In Korea, up to 80 percent of the death rate can be reduced from 1.75 to 0.33 thereby reducing burden of disease although new cases are increasing but the number of patients hospitalized or the severity is decreasing.”

– .